According to an editorial, the overall cost of treatment is also a consideration, with price of 1 year of maintenance lenalidomide of more than $120,000 in US. It notes that an ongoing U.S. trial that was prospectively planned as a companion to the current study has a nearly identical design, except that maintenance lenalidomide is being administered until myeloma progression. It suggests that the combined results of the trials will be of interest, particularly within biologically defined risk groups and among patients in whom minimal residual disease is not detected. It highlights that “the added value of extended maintenance therapy will be dubious unless an improvement in overall survival is established, and given the prices of the new drugs, the price of transplantation, which was once considered to be prohibitively expensive, now represents a relatively small part of the overall monetary cost of the treatment program.”